ClinicalTrials.gov
ClinicalTrials.gov Menu

Changes in Alveolar Macrophage Function During Acute Lung Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02693912
Recruitment Status : Unknown
Verified February 2016 by Chunling Jiang, West China Hospital.
Recruitment status was:  Not yet recruiting
First Posted : February 29, 2016
Last Update Posted : February 29, 2016
Sponsor:
Information provided by (Responsible Party):
Chunling Jiang, West China Hospital

Brief Summary:
In this study, the investigators aim to observe the change in alveolar macrophage function during acute lung injury.

Condition or disease Intervention/treatment
Acute Lung Injury Procedure: Bronchoscopy

Detailed Description:
Alveolar macrophages are tissue-resident or recruited cells with key functions in recognition of pathogens, initiation of host defensive ang protective inflammation,and in clearance of pathogens from the airways. However, macrophages are also responsible for efficient clearance of apoptotic neutrophils, termed efferocytosis, which is a prerequisite for the timely resolution of inflammation. In this study, the investigators aim to observe the change in alveolar macrophage function during acute lung injury.

Study Type : Observational
Estimated Enrollment : 25 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Changes in Alveolar Macrophage Function During Acute Lung Injury
Study Start Date : September 2016
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : August 2018


Group/Cohort Intervention/treatment
acute lung injury
Patients with a diagnosis of acute lung injury (ALI) under mechanical ventilation.Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
Procedure: Bronchoscopy
Bronchoscopy will be implemented under sedation in both groups.

control
Patient under mechanical ventilation without any lung diseases. Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
Procedure: Bronchoscopy
Bronchoscopy will be implemented under sedation in both groups.




Primary Outcome Measures :
  1. alveolar macrophages (AMs) phagocytic index [ Time Frame: 7 days after admission ]
    AMs will be collected and cultured in vitro. Apoptotic neutrophils will then be cocultured with AMs for 1 hour. To measure phagocytosis of apoptotic neutrophils, AMs were further processed and phagocytosed apoptotic neutrophils were detected by confocal fluorescence microscopy as described below under Cell staining and confocal microscopy. The phagocytic index was calculated according to the following formula: phagocytic index = (total number of engulfed cells/total number of counted macrophages) × (number of macrophages containing engulfed cells/total number of counted macrophages) × 100.


Secondary Outcome Measures :
  1. 30 days mortality [ Time Frame: 30 days after admission ]

Biospecimen Retention:   Samples With DNA
bronchoalveolar lavage fluid will be collected which contains immune cells, including macrophages.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
ALI and acute respiratory distress syndrome (ARDS) are characterized by an increased permeability of the alveolar-capillary barrier resulting in lung edema with protein-rich fluid, thus resulting in impairment of arterial oxygenation. ALI/ARDS is defined as a lung disease with acute onset, noncardiac, diffuse bilateral pulmonary infiltrates and a paO2/FiO2 ≤ 300 for ALI or a paO2/FiO2 ≤ 200 for ARDS. The ageadjusted incidence of ALI/ARDS is estimated with 86.2 per 100,000 person-years. Despite all innovations in intensive care medicine, the mortality of ARDS remains up to 40%.
Criteria

Inclusion Criteria:

  • Patients in ICU with diagnosed ALI under mechanical ventilation

Exclusion Criteria:

  • Patients with cardiac dysfunction, using steroid drugs or other drugs can that affect efferocytosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02693912


Contacts
Contact: Chunling Jiang jiang_chunling@yahoo.com

Sponsors and Collaborators
West China Hospital
Investigators
Study Chair: Jin Liu West China Hospital

Responsible Party: Chunling Jiang, Dr., West China Hospital
ClinicalTrials.gov Identifier: NCT02693912     History of Changes
Other Study ID Numbers: wch-150718
First Posted: February 29, 2016    Key Record Dates
Last Update Posted: February 29, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: no plan has been made to share data

Keywords provided by Chunling Jiang, West China Hospital:
efferocytosis
macrophage

Additional relevant MeSH terms:
Wounds and Injuries
Lung Injury
Acute Lung Injury
Respiratory Distress Syndrome, Adult
Lung Diseases
Respiratory Tract Diseases
Thoracic Injuries
Respiration Disorders